Search

Introduction: Luminal tumors show molecular differences and different behavior. The antigen Ki67 is one of the factors that differentiate between luminal A and B. Genomic platforms can identify which patients will benefit from chemotherapy. Objectives: To establish if there is an association between ki67 and Oncotype Dx Score (RS). To assess the influence of ki67 and RS on the therapeutic decision, to evaluate the association between clinical risk and RS, between lymphovascular invasion (LVI) and RS, and between positive axillar nodes (up to 1 node) and RS. Materials and methods: Retrospective, observational, descriptive study. We included 68 patients with negative Her2Neu luminal tumors, T1-T2, negative or positive axillary up to 1 node, who performed Oncotype DX between 2009 and 2020 at Hospital Alemán. They were classified into RS less than or equal to 25 and greater than 25 based on the TAILORx study, where it was shown that overall there is no benefit from chemotherapy between 0-25. Results: An association was observed between ki67 and RS in 44 (64.7%) patients and it was greater between low ki67 and RS less than or equal to 25 (77.3%). The treatment was based on RS. An association between clinical risk and RS was observed in 43 (63.2%) patients, and it was greater between low clinical risk and RS less than or equal to 25 (87.5%). In 88.8% there was no association between LVI and RS, as well as between positive axillary up to 1 node and RS in 85.7%. Conclusion: It is necessary to offer every patient with a luminal tumor a genomic platform since both ki67 and other pathological clinical factors alone did not prove to be superior or sufficient.

Introduction: Numerous publications have individually evaluated the expression of the p53 protein, the presence of androgen receptors and the magnitude of the lymphocyte infiltrate TILs in triple negative tumors. The presence or absence of these variables could help identify subgroups in triple negative breast cancer (TNBC). Objectives: The objective of this study is to evaluate in triple negative tumors feasibility of using lymphocyte infiltration, the expression of p53 protein and androgen receptors as prognostic markers (overall survival and disease-free) .and collaborate in the identification of biomarkers for the development of specific target treatments. Material and Methods: We intend to analyze those patients diagnosed with TNBC treated at the German Hospital of Buenos Aires and at the Mater Dei Sanatorium from December 2002 to December 2014. Results: Thirty-five patients with TNBC were analyzed. The prevalence in the p53 mutation was 57% in the general population, 64,7% in relapses and 69% in deceased patients. 22.8% of the patients studied showed expression of androgenic receptors. The average lymphocytic tumor infiltration (TILs) was 20.6% (5%-70%), being lower when the population of patients who relapsed was only evaluated (19.6%) and even lower when evaluating the population of deceased patients (17.1%). Discussion: The mutation in p53 in our population has a RR of 1.6 for survival with a p = 0.596. The presence of ILV together with the mutation in p53 constitutes a mortality risk factor with p = 0.0147. The expression of androgenic receptors has a RR of 1.5 as a mortality risk factor and a p: 0.974. The presence of TILS greater than 20% is predictive of mortality and recurrence with a p: 0.0269. This is maintained with values of TILs of 18% and 15% with p = 0.0131 and p = 0.0032 respectively. Conclusion: The determination of the TILs together with the evaluation of the mutation of the p53, and its evaluation in combination with other prognostic factors (ILV and Ki67) is useful for predicting prognosis in the TNBC. We think that the presence of mutation of p53 and the degree of TILs are determinations whose evaluation should be standardized in patients with TNBC and be duly recorded in the pathology report.

Background: Near-infrared fluorescence-based sentinel lymph node (SLN) mapping technique with indocyanine green (ICG) has been found a useful surgical modality for sentinel node detection and disease staging in endometrial cancer (EC) worldwide. Objective: We aimed to introduce the SNL mapping technology using ICG and Near Infrared (NIR) fluorescence in Argentina. We aimed to assess the overall and bilateral detection rate of ICG based SNL mapping along with verifying its feasibility and effectiveness in surgical staging. We also aimed to discover the perceptions of surgeons regarding the use of ICG as a tracer and NIR as light-medium in SNL mapping. Method: ICG SLNs identification was evaluated retrospectively. This study was performed at the Hospital Aleman de Buenos Aires in September, 2017The detection rates were calculated along with the analysis of the number of SNL observed and operative time, and time taken by overall surgery. Subsequently, the surgeons were interviewed to ascertain their opinion of using ICG SNL mapping in endometrial cancer staging. Results: Four patients with endometrial cancer were included for analysis. The overall and bilateral detection rates have been 100% and 75%, respectively. While, under white light, no SLNs were identified. The average operative time of nodes resection was estimated 2.15 minutes. The fluorescence has been used for 2.2 minutes and overall time taken by surgery was estimated 71.5 minutes. The estimated blood loss (EBL) has been lower than 50 ml. The responses of surgeons’ from the interview have been 100% positive. The cost of the procedure based on the amount of dye used was 25 dollars per patient. Conclusion: Laparoscopic ICG SLN resulted to be feasible, practical and no expensive surgical modality for uterine cancer triage.